Bioxytran, Inc.

Equities

BIXT

US09075D1028

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:44:45 10/05/2024 BST			5-day change	1st Jan Change
0.1106 ^USD	+0.55%		+9.40%	-26.27%

04-19	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-19	Bioxytran, Inc. Announces Board Changes	CI

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

April 19, 2024 at 09:50 pm

Bioxytran, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.800329 million compared to USD 0.785083 million a year ago.

Latest news about Bioxytran, Inc.

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Bioxytran, Inc. Announces Board Changes	04-19	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist	03-06	CI
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19	02-21	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M	24/08/23	CI
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients	08/08/23	CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23	CI
China metals export curbs lift shares in US producer MP Materials	05/07/23	RE
China rare earth curbs lift shares in U.S. producer MP Materials	05/07/23	RE
Bioxytran, Inc. announced that it expects to receive $0.5 million in funding from Triton Funds, LLC	07/06/23	CI
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Bioxytran, Inc. Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	19/04/23	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Bioxytran, Inc. Announces Positive Phase 2 Trial Results	29/03/23	CI
Bioxytran, Inc. announced that it has received $0.13 million in funding	12/03/23	CI
Bioxytran, Inc. Announces Vitro Testing At Foundation for Neglected Disease Research in Bangalore India	28/02/23	CI
Bioxytran, Inc. Receives Approval to Initiate Trials with Prolectin-I	06/02/23	CI
Bioxytran, Inc. Announces Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial	28/12/22	CI
Bioxytran Establishes Indian Subsidiary Pharmalectin India Private Limited in Preparation of Commercialization	14/12/22	CI
Bioxytran Receives Approval to Optimize Dosage in Covid-19 Patients	08/12/22	CI
Bioxytran, Inc. announced a financing transaction	27/11/22	CI
BIOXYTRAN, INC. Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print	16/11/22	CI

Chart Bioxytran, Inc.

Duration

Period

More charts

Company Profile

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOXYTRAN, INC.	-26.27%	19.35M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs